We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Haleon Plc | LSE:HLN | London | Ordinary Share | GB00BMX86B70 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.50 | -0.13% | 379.00 | 6,040,713 | 12:53:08 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 378.90 | 379.10 | 381.20 | 378.40 | 380.70 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Offices-holdng Companies,nec | 11.3B | 1.05B | 0.1150 | 32.96 | 34.62B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 12:53:56 | O | 391 | 379.0359 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 04/10/2024 | 16:30 | UK RNS | Haleon PLC Holding(s) in Company |
| 04/10/2024 | 14:30 | UK RNS | Haleon PLC Holding(s) in Company |
| 03/10/2024 | 17:29 | ALNC |  IN BRIEF: Haleon buys GBP230 million in shares from Pfizer |
| 03/10/2024 | 12:30 | UK RNS | Haleon PLC Completion of off-market purchase and Total Voting |
| 03/10/2024 | 10:45 | UK RNS | Haleon PLC Director Declaration |
| 01/10/2024 | 18:00 | UK RNS | FTSE Russell Haleon |
| 01/10/2024 | 10:03 | ALNC | UPDATE: Pfizer cuts stake in Haleon to 15% with GBP2.7 billion sale |
| 01/10/2024 | 07:01 | UK RNS | Haleon PLC Update on purchase alongside Pfizer offering |
| 01/10/2024 | 07:00 | UK RNS | Goldman Sachs International Pricing of Offering of Ordinary Shares in.. |
| 30/9/2024 | 21:59 | ALNC | TOP NEWS: Pfizer to raise around GBP2.7 billion from Haleon stake sale |
Haleon (HLN) Share Charts1 Year Haleon Chart |
|
1 Month Haleon Chart |
Intraday Haleon Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 11:53:57 | 379.04 | 391 | 1,482.03 | O |
| 11:53:30 | 379.04 | 143 | 542.02 | O |
| 11:53:08 | 379.00 | 2 | 7.58 | AT |
| 11:52:55 | 379.00 | 2 | 7.58 | AT |
| 11:51:16 | 379.00 | 1,854 | 7,026.66 | AT |
| Top Posts |
|---|
Posted at 09/10/2024 09:20 by Haleon Daily Update Haleon Plc is listed in the Offices-holdng Companies,nec sector of the London Stock Exchange with ticker HLN. The last closing price for Haleon was 379.50p.Haleon currently has 9,123,638,944 shares in issue. The market capitalisation of Haleon is £34,578,591,598. Haleon has a price to earnings ratio (PE ratio) of 32.96. This morning HLN shares opened at 380.70p |
Posted at 08/10/2024 11:02 by philanderer UBS raises Haleon price target to 445 (410) pence - 'buy'Deutsche Bank raises Haleon price target to 375 (340) pence - 'hold' Barclays cuts Haleon price target to 406 (407) pence - 'overweight' |
Posted at 01/10/2024 10:27 by philanderer (Alliance News) - Pfizer Inc sold a 7.6% stake in consumer health products firm Haleon PLC for GBP2.7 billion, the investment banks running the offer confirmed on Tuesday.Pfizer, a New York-based pharmaceuticals firm, sold 640 million Haleon shares at 380 pence per share in a placing run by Goldman Sachs International and BofA Securities as joint global coordinators. Haleon bought back an additional 60.5 million shares from Pfizer at the same price. As a result, Pfizer's stake in Haleon has been reduced to 15.0% from 22.6%. |
Posted at 01/10/2024 10:09 by philanderer Pfizer's holding of HLN will now be down to appx 15% after these transactions. |
Posted at 01/10/2024 00:40 by philanderer And HLN buying £230 million worth from Pfizer subject to completion of Pfizer's offering |
Posted at 25/9/2024 12:03 by anhar Yes they have. As you say HLN has shown high growth, in my case against my personal demerger tax base cost of about 249p. That figure will vary for everyone as it depends on their original cost of old GSK.But as I've said I'm only in shares for the divis and as such have been running an income port for decades, not for capital gains, though the latter are of course welcome. I hold very long term in most cases and will definitely be retaining my HLN stock. |
Posted at 24/9/2024 10:58 by anhar I'd add bid potential to the reasons for the high rating. There was already an abortive bid from Unilever just prior to the GSK demerger so I expect many people think that HLN may be taken out at some stage.I retained my demerger HLN shares which have shown excellent growth, driving up the rating, though I'm just an income investor and it has demonstrated decent divi growth over its short independent existence. |
Posted at 10/9/2024 19:57 by philanderer :-)September 10, 2024 11:41 AM EDT BofA Securities analyst Victoria Petrova raised the price target on Haleon PLC (HLN:LN) to GBP4.40 (from GBP4.00) streetinsider.com |
Posted at 10/9/2024 14:02 by mattboxy Hopefully that will firm up the share price! |
Posted at 19/5/2024 10:04 by philanderer Yes, I would have thought so. This from early april.Haleon overhang can be gone in a year, suggests Barclays One of the biggest drags on the share price of consumer group Haleon might be gone by the end of the year suggests Barclays. According to the broker, and based on Pfizer's latest placing, it's possible it and GSK will have entirely sold down by the end of this year, leaving Haleon 100% free float, said the broker. “Given repeated investor feedback about the overhang being a barrier to share price performance, we think this could be a significantly helpful potential catalyst.” Currently, Pfizer has 2062m shares in Haleon (22.6%) and GSK has 385m (4.2%) for a total overhang of 27%, down from 45% in May 2023 before the first GSK placing. “The pace of sell-down is accelerating and our analysis shows Haleon could be overhang-free by year-end at the current rate of progress,” said the broker. “With a 90-day lockup from the Mar24 placing, there is time for three more placings before year-end, assuming the lockup remains unchanged. “Haleon also has £185m remaining in its announced buyback plans for this year, which is 57m shares at the current share price. This would leave an overhang of 18m shares, or 0.2% of Haleon, less than a rounding error.” Barclays sees the overhang as a key reason for Haleon’s strong sales performance since its split from GSK has failed to translate into a better share price performance. “When Haleon spun in summer 2022 there was considerable scepticism about its 4-6% organic sales growth target, yet that year it delivered 9%. “Then there was considerable scepticism about it delivering 4-6% in 2023 given the 9% comp, yet last year it delivered 8%. Barclays added that Haleon remains one of its most preferred names within European Consumer Staples, a sector it sees as highly attractive, and potentially consolidating. The broker has a price target of 390p for Haleon and an overweight rating. proactiveinvestors.c |
Posted at 15/12/2023 13:45 by anhar Trailing yield is actually 1.3%. This is based on last 12m divis total 4.2p (22 final of 2.4p plus 23 interim 1.8p) on the share price of 319p. The 23 forecast is for 5.5p making a forward yield of 1.7%.Still very low though. I hold HLN acquired via the GSK demerger and what may be supporting the price, if you think there is a reason other than the normal random walk of share prices, is bid hopes, as you suggest. Everyone thinks that, making it less likely! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
